ProCE Banner Activity

CALGB 140503 (Alliance): Phase III Trial of Lobar or Sublobar Resection for Peripheral Clinical Stage IA NSCLC With Tumor Size ≤2 cm

Slideset Download
Conference Coverage
Sublobar resection resulted in noninferior DFS and OS compared with lobectomy for patients with peripheral cT1aN0 NSCLC and tumor size ≤2 cm without metastases to major hilar and mediastinal lymph nodes.

Released: August 19, 2022

Expiration: August 18, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc